946,326 Shares in AbbVie Inc. $ABBV Bought by SEB Asset Management AB

SEB Asset Management AB purchased a new stake in shares of AbbVie Inc. (NYSE:ABBV) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 946,326 shares of the company’s stock, valued at approximately $205,816,000. AbbVie accounts for about 0.9% of SEB Asset Management AB’s portfolio, making the stock its 17th biggest position.

Several other large investors have also made changes to their positions in ABBV. Litman Gregory Wealth Management LLC purchased a new stake in shares of AbbVie during the fourth quarter worth about $28,000. Westend Capital Management LLC bought a new stake in AbbVie during the 4th quarter valued at approximately $29,000. Imprint Wealth LLC lifted its holdings in AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after purchasing an additional 45 shares in the last quarter. Legacy Wealth Managment LLC ID lifted its holdings in AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after purchasing an additional 73 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. bought a new position in AbbVie in the 4th quarter worth approximately $31,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s Allergan Aesthetics unit won European Commission approval for Boey® (trenibotulinumtoxinE), a new facial injectable for glabellar lines. The approval gives AbbVie a differentiated aesthetics product in all 30 EEA countries and could add another growth driver to offset Humira-related declines. Article Title
• Positive Sentiment: Investors are also focusing on AbbVie’s neuroscience franchise and other newer product catalysts, with analysts expecting solid Q2 growth and continued momentum from brands such as Vyalev, RINVOQ, and SKYRIZI ahead of earnings. Article Title
• Positive Sentiment: Brokerage sentiment remains constructive, with recent coverage showing a “Moderate Buy” consensus and multiple price-target increases in July, reinforcing confidence in AbbVie’s long-term pipeline and earnings outlook. Article Title
• Neutral Sentiment: Erste Group slightly lowered its FY2026 EPS estimate for AbbVie to $14.08 from $14.23, though the new estimate remains close to the consensus of $14.18 and is not a major deviation. Article Title

AbbVie Price Performance

NYSE:ABBV opened at $254.53 on Friday. The company has a market cap of $449.70 billion, a price-to-earnings ratio of 125.38, a PEG ratio of 0.84 and a beta of 0.30. AbbVie Inc. has a 1 year low of $184.63 and a 1 year high of $261.64. The stock’s 50 day simple moving average is $229.80 and its two-hundred day simple moving average is $221.94.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. During the same period in the prior year, the company earned $2.46 EPS. The company’s quarterly revenue was up 12.4% compared to the same quarter last year. As a group, analysts anticipate that AbbVie Inc. will post 14.18 EPS for the current year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. AbbVie’s dividend payout ratio is presently 340.89%.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Bank of America lifted their price objective on shares of AbbVie from $234.00 to $276.00 and gave the company a “buy” rating in a research report on Friday, July 10th. Wells Fargo & Company upped their target price on shares of AbbVie from $260.00 to $295.00 and gave the stock an “overweight” rating in a research report on Friday, July 10th. Guggenheim upped their target price on shares of AbbVie from $249.00 to $261.00 and gave the stock a “buy” rating in a research report on Thursday, July 9th. Citigroup raised their target price on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Wednesday. Finally, Royal Bank Of Canada lifted their price target on shares of AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a report on Friday, July 10th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $267.67.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.